

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Tradomark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.insto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/691,344	10/18/2000	Gregory Donoho	LEX-0071-USA	3961
24231 75	590 03/27/2002			
LEXICON GENETICS INCORPORATED 8800 TECHNOLOGY FOREST PLACE			EXAMINER	
THE WOODLANDS, TX 77381-1160			MITRA, RITA	
			ART UNIT	PAPER NUMBER
			1653	a
			DATE MAILED: 03/27/2002	9

Please find below and/or attached an Office communication concerning this application or proceeding.



File Copy

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 2023

APPLICATION NO./ CONTROL NO. 10/18/2000 FIRST NAMED INVENTOR / PATENT IN REEXAMINATION Gregory Donoho	
-------------------------------------------------------------------------------------------------------	--

RITA MITRA

ART UNIT PAPER

1653 9

DATE MAILED:

PI ase find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed 01 February, 2002 is not fully responsive to the Office communication mailed 17 December, **2001** for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the reply appears to be <u>bona fide</u> attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE** (1) **MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Rita Mitra, Art Unit 1653, whose telephone number is (703) 605-1211.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio
(http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE)

2. Mailed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:

U. S. Patent and Trademar 2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1803
Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at: 2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1803, Box Sequence, Arlington, Virginia 22202

Christopher S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

File	Copy
Applicant(s)	

09/691344

Application No.

Donoho et al. Art Unit

Examiner

Rita Mitra, Ph. D.

1653

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☑ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ∑ 5. The computer readable form that has been filed with this application has been found to be damaged. and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200 To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY